A Global Mission to Reduce Heart Disease

Dr. Kamal Morar is a physician, healthcare entrepreneur, and philanthropist dedicated to reducing heart disease by addressing metabolic health—especially in South Asians who comprise 25% of the world’s population yet endure over 60% of all heart attacks worldwide.

Founder of LPS Health

As Founder and Chief Medical Officer of the nonprofit LPS Health, Dr. Morar focuses his mission on innovative prevention strategies—particularly highlighting the powerful role of weight loss and intermittent fasting in improving metabolic conditions such as diabetes, high blood pressure, and cholesterol issues..

Empowering Communities Through Education

By promoting culturally relevant education around these proven lifestyle changes, his organization empowers individuals to take control of their health and lower their risk of heart disease and stroke for the long term.

Leading With Experience and Compassion

Dr. Morar’s work includes building accessible outpatient care models for vulnerable populations, leading charitable projects to bring prevention and treatment to rural India, and mentoring young clinicians. Inspired by his own experiences overcoming metabolic syndrome and diabetes, he advocates for prevention-first, real-world solutions rooted in research, lifestyle change, and community education.

A Global Movement for Better Metabolic Health

Through LPS Health, he aims to create a global movement for improving metabolic health through fasting and weight loss—giving communities the knowledge and tools to live healthier, longer lives.

About

Founder: Kamal Morar, MD, MBA

Bariatric arterial embolization has emerged as an active and promising field in Interventional Radiology, forged by a small group of pioneering researchers and clinicians.

Dr. Kamal Morar, MD, MBA stands at the forefront of outpatient Interventional Radiology and bariatric embolization. Over 21 years, Dr. Morar has performed over 30,000 interventional radiology procedures, including more than 5,000 embolizations, and co-authored the pivotal GET LEAN Study (“Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically”)—the first peer-reviewed human trial of BAE published in the Journal of Vascular and Interventional Radiology (JVIR).

This foundational research provided the earliest clinical demonstration of left gastric artery embolization yielding marked appetite suppression and weight loss in morbidly obese patients, and it reported not only technical feasibility but also key safety findings, including the absence of major complications and rapid resolution of minor adverse events¹⁹.

Take Risk Assessment Now

Clinical Leadership and Research

Pioneering studies and ongoing trials collectively demonstrate that BAE is technically reproducible, broadly safe, and—when successful—provides meaningful weight loss and appetite suppression for morbidly obese and overweight patients. The current consensus supports its use in select populations who cannot undergo surgery or who prefer a minimally invasive alternative, with indications expanding as data matures²⁰²¹²²²³.

Dr. Morar’s work, alongside international teams, continues to define the procedural standards, refine technical methodology, and establish evidence for patient selection and peri-procedural care. Their ongoing research shapes both the regulatory pathways and broader clinical adoption of BAE in the fight against obesity.

Take Risk Assessment Now

Annotated Bibliography

^{¹⁹ Kamal Morar, MD—Patient Reach 360 | GET LEAN Study, Journal of Vascular and Interventional Radiology: First peer-reviewed trial establishing feasibility and foundational safety data for LGA embolization in severe obesity.}

^{²⁰ Bariatric Embolization: Are Patients Actually Losing Weight? (Endovascular Today, 2018): GET LEAN and early pilot trial descriptions including patient weight loss, appetite suppression, and minor adverse events.}

^{²¹ Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Study)—Radiology, 2019: Largest multicenter prospective study, reporting 12-month safety, technical feasibility, and metabolic benefits.}

^{²² Metabolic Effects of Bariatric Arterial Embolization vs Bariatric Surgery—CenterWatch, clinical trial NCT05859022: Ongoing two-year study comparing surgery and BAE for diabetes and metabolic improvement.}

^{²³ Bariatric embolization with N-butyl cyanoacrylate glue: a revival—PMC, 2025 & Bai et al’s Chinese multi-arm trial: International randomized trials, larger sample sizes, robust ghrelin suppression, MRI data, and safety profile.}